Table 2.
Training activity | Country | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CZE | FRA | DEU | HUN | IRL | ITA | NOR | PRT | SVK | ESP | CHE | |
GCP | X | X | X | X | X | X | X | X | X | X | |
Study nurse/coordinator | X | X | X | X | X | (X) | X | (X) | X | X | |
Investigator | X | X | X | X | X | X | X | X | X | X | |
Monitoring | X | X | X | X | X | X | X | X | |||
PV/clinical pharmacology | X | X | X | X | (X) | X | X | ||||
Principal investigator | X | X | X | X | X | X | X | ||||
CRO operators | X | X | X | ||||||||
Methodology | X | X | X | X | X | ||||||
QMS | X | X | X | X | X | ||||||
Postgraduate | X | X | X | X | X | X | X | X | |||
Other | X | X | X | X | X |
X = available, (X) = planned
CZE Czech Republic, FRA France, DEU Germany, HUN Hungary, IRL Ireland, ITA Italy, NOR Norway, PRT Portugal, SVK Slovakia, ESP Spain, CHE Switzerland, GCP Good Clinical Practice, PV pharmacovigilance, CRO clinical research organization, QMS quality management system